VEGF gene therapy in angina patients
This article has no abstract so we have provided the first paragraph of the full text.
Results from a phase II trial suggest that vascular endothelial growth factor (VEGF) gene transfer is safe and might produce an anti-ischemic effect in patients with chronic, stable myocardial ischemia.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
